Abstract
The clinical introduction of magnetic hyperthermia therapy (MHT) has been hindered by current available agents with poor magnetic-to-thermal conversion efficiency and biocompatibility. It is believed that the genetically engineered magnetic nanocages of encapsulin-produced magnetic iron oxide nanocomposites (eMIONs) have great potential as clinically translatable MHT agents for cancer magneto-catalytic theranostics.